NeuroPace Inc (NPCE) PT Raised to $20 at Leerink Partners

Leerink Partners analyst Mike Kratky raised the price target on NeuroPace Inc (NASDAQ: NPCE) to $20.00 (from $19.00) while maintaining a Outperform rating.

The analyst comments "We are updating our model following NPCE's preliminary 4Q25 and FY26 financial disclosures. See our Jan 13 note HERE. The net effect of these changes leads to our new $20 price target (from $19 prior). NPCE is still targeting potential FDA approval of RNS in idiopathic generalized epilepsy (IGE) in 2H26, which we believe could ultimately represent a transformational catalyst for the stock. In the meantime, we remain encouraged by NPCE's ongoing commercial momentum in its core RNS business in adult focal drug-resistant epilepsy (DRE) patients. Overall, we continue to like the current risk/reward setup for NPCE as the company capitalizes on several ongoing growth drivers and could be well positioned to see meaningful upside in 2H26 in the event RNS gains FDA approval in IGE. Reiterate OP."

You May Also Be Interested In

• NeuroPace (NPCE) Reiterated at Overweight by Cantor Fitzgerald on Commercial Momentum
• Iran to escalate tensions in region if diplomacy with U.S. fails - Reuters
• Nvidia to invest $1.5B in SB Energy for Ohio AI campus with OpenAI